In clinical practice, tumor tissues are insufficient for EGFR genotyping in at least 20% of advanced NSCLC patients for various reasons including insufficient availability of neoplastic tissue, lack of appropriate tumor tissue for biopsy, or that a biopsy is not technically feasible 11, 12. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.